Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Rep. Kennedy to join Ambien lawsuit?

Executive Summary

Rep. Patrick Kennedy (D-R.I.) says he will check himself into the Mayo Clinic for rehab after he ran into a security barrier in Washington, D.C. May. When Capitol Police picked up the disoriented congressman at 2:45 a.m., he claimed he was headed to the Capitol for a vote. In a statement, Kennedy maintained that he was not under the influence of alcohol at the time of the incident, but admitted to having taken Sanofi-Aventis' insomnia therapy Ambien and Wyeth's antihistamine Phenergan. A recently filed class action lawsuit alleges Sanofi failed to adequately warn patients of risk of sleep walking and eating with Ambien (1"The Pink Sheet" March 20,2006, p. 18)...

You may also be interested in...

Ambien Not Sleepwalking Through Scrutiny; Label Warnings Updated

Sanofi's sleeping pill has been revised once again in an update that also limits the recommended dosing.

Ambien Class Action Suit May Serve As Wake-Up Call For Competitors

A civil class action lawsuit in Manhattan federal court alleging that Sanofi-Aventis failed to adequately warn patients of the risk of sleep walking and sleep eating with Ambien (zolpidem) could open the door for other agents in the highly competitive sleep category

Amgen/AstraZeneca’s Tezepelumab Cuts Asthma Exacerbations By 56%

Data presented at AAAI meeting show reduced annualized asthma exacerbation rates across all patient populations, but doctors are unlikely to switch patients served well by existing biologics. 




Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts